-
1.发明授权公开(公告)号：US11846642B2
公开(公告)日：2023-12-19
申请号：US16536777
申请日：2019-08-09
IPC分类号： C07K14/12 , C07K14/705 , G01N33/537 , G01N33/58 , G01N33/68 , G01N33/94 , C07K14/54 , G01N33/564
CPC分类号： G01N33/94 , C07K14/5434 , C07K14/70546 , G01N33/537 , G01N33/564 , G01N33/58 , G01N33/6854 , C07K2319/20 , C07K2319/50 , G01N2333/54 , G01N2333/5434 , G01N2333/70546 , G01N2800/065 , G01N2800/52
摘要： The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
-
2.发明公开公开(公告)号：US20240183867A1
公开(公告)日：2024-06-06
申请号：US18485566
申请日：2023-10-12
IPC分类号： G01N33/94 , C07K14/54 , C07K14/705 , G01N33/537 , G01N33/564 , G01N33/58 , G01N33/68
CPC分类号： G01N33/94 , C07K14/5434 , C07K14/70546 , G01N33/537 , G01N33/564 , G01N33/58 , G01N33/6854 , C07K2319/20 , C07K2319/50 , G01N2333/54 , G01N2333/5434 , G01N2333/70546 , G01N2800/065 , G01N2800/52
摘要： The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.
-
搜索结果
2 条记录 (耗时 0.016 秒)
